Ipsen Sa S/Adr (IPSEY) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ipsen Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.978 Hello and welcome to Ibsen's conference call and webcast on Q1 2026 results. 00:00:05.978 -- 00:00:10.224 I'll now hand you over to David Lowe, Ibsen's CEO. 00:00:10.224 -- 00:00:14.990 Thank you, operator, and hello everyone. I'm pleased to welcome you this afternoon to 00:00:14.990 -- 00:00:19.596 our Q1 sales presentation, which can also be found on Ibsen.com. 00:00:19.596 -- 00:00:22.099 Please turn to slide two. 00:00:22.099 -- 00:00:26.504 Please take note of our forward-looking statements, which outline the routine risks and 00:00:26.504 -- 00:00:29.188 uncertainties contained within this presentation. 00:00:29.188 -- 00:00:33.610 Also, All of my comments on growth will be based on constant exchange rates. 00:00:33.610 -- 00:00:36.611 Please turn to slide three. 00:00:36.894 -- 00:00:41.119 I'm going to take you through our first quarter sales performance and provide you with 00:00:41.119 -- 00:00:46.165 a business update, after which our CFO, Aymeric Le Chatelier, will join me 00:00:46.165 -- 00:00:51.271 for the Q&A session. Let's begin by taking a look at today's highlights. 00:00:51.271 -- 00:00:54.232 Please turn to slide four. 00:00:54.419 -- 00:00:58.085 We delivered a strong top-line growth in Q1. 00:00:58.085 -- 00:01:01.451 Total sales grew by 22.6% this 00:01:01.451 -- 00:01:05.518 quarter, driven by all three therapeutic areas. 00:01:05.518 -- 00:01:11.008 We're pleased to see the very strong performance of our portfolio outside somatolin, 00:01:11.008 -- 00:01:14.373 which grew by 27.5% in the 00:01:14.373 -- 00:01:16.297 three-month period. 00:01:16.297 -- 00:01:21.513 Based on this continued solid momentum and strong growth, We confirm our 00:01:21.513 -- 00:01:26.700 2026 guidance with total sales growth grea...